Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity

Published:2014-01 Issue: Volume:79 Page:9-12
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Slavin Shimon,Moss Ralph W.,Bakacs Tibor^ORCID

Publisher

Elsevier BV

Subject

Pharmacology

Reference26 articles.

1. Response to “Ipilimumab (Yervoy) and the TGN1412 catastrophe”;Curran;Immunobiology,2012

2. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

3. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma;Robert;N Engl J Med,2011

4. Nivolumab plus ipilimumab in advanced melanoma;Wolchok;N Engl J Med,2013

5. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation;Bashey;Blood,2009

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tackling cancer cell dormancy: Insights from immune models, and transplantation;Seminars in Cancer Biology;2022-01

2. Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution;Cancer Immunology, Immunotherapy;2020-11-05

3. Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies;Cancer Immunology, Immunotherapy;2020-03-09

4. Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer;Scandinavian Journal of Immunology;2019-10-07

5. MiStImm: an agent-based simulation tool to study the self-nonself discrimination of the adaptive immune response;Theoretical Biology and Medical Modelling;2019-05-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3